ArticleDiscover oncology2025
The effect of radiotherapy on patients with EGFR-driven lung cancer brain metastasis: a systematic review and meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Caffeic acid for the management of leukopenia: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2026Pooled it
- Impact of probiotic supplementation on serum levels of brain-derived neurotrophic factor: GRADE-based dose-response meta-analysis.BMC nutrition · 2025Pooled it
- Association between high-sensitivity C-reactive protein and diabetic nephropathy: a systematic review and meta-analysis.BMC nephrology · 2025Pooled it
- Efficacy and safety of external phytotherapy in diabetic foot ulcers: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2026Review
- Association of CALLY index with NAFLD in U.S. adults from NHANES 2017-2020 assessed by vibration-controlled transient elastography.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases (BMs) are a common and fatal consequence in patients with advanced malignancies. Mutations happening in the epidermal growth factor receptor (EGFR) are associated with an elevated risk BMs, occurring in approximately 20-40% of patients. This study evaluates the safety and efficacy of different radiotherapy (RT) modalities in patients with EGFR-mutant lung cancer brain metastases.
methodThis study was conducted according to the PRISMA guideline. A comprehensive search was conducted on PubMed, Embase, Web of Science, and Scopus, until 13 March 2024. Stata v.17 was used for statistical analysis.
resultA total of 57 studies involving 4614 patients were analyzed, with a female predominance of 59.55% and a mean age of 50-70 years. The 6-month overall survival (OS) rate was 94% [95% CI 91-96%], 81% [95% CI 78- 84%] at 1-year, 55% [95% CI 50-60%] at 2-year, 37% [95% CI 32-42%] at 3-year, decreasing to 21% [95% CI 16-26%] at 5 years. Progression-free survival (PFS) rates were 84% [95% CI 79-89%] at 6 months and 20% [95% CI 14-26%] at 3 years. Meta-regression analysis indicated that a higher number of metastases, Karnofsky performance status below 80, and an ECOG score over one were significantly linked to OS outcomes.
conclusionRT significantly improves survival outcomes in patients with EGFR-mutant brain metastases. However, the combination of RT with targeted therapies, such as tyrosine kinase inhibitors (TKIs), appears to offer more favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.